Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

February 23, 2018

Responsive image

THOUSAND OAKS, Calif., Feb. 23, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA® (denosumab) to cover…

Category: Precious Metals